Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study

Related Clinical Trial
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring Educational Video’s Impact on Knowledge Regarding Cervical Cancer Screening Primary Cervical Cancer Screening by Self-sampling HPV Test Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2) Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022 Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests Diagnostic Cervical Conization for Persistent Infection or Integration of HPV DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment Cervical Cancer Screening Strategies DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening The Organ Transplant Recipient HPV and Skin Cancer Study Effect of HPV Integration on Prognosis of Young Women With CIN2 in China Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Prevention and Screening Towards Elimination of Cervical Cancer HPV-based Screening Among Women 23-29 Years of Age Clinical Evaluation of Detection of High Risk HPV in Urine The Vaginal Microecology and Innate Immunity After Focused Ultrasound Ablation Treatment for CIN Large Loop Excision of the Transformation Zone (LLETZ) With vs Without IntraOperative Application of Lugol’s Iodine Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia Optimization of Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico Low-cost Imaging Technology for Global Prevention of Cervical Cancer Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia Depth of Necrosis in Normal Cervical Epithelium After 85% Trichloroacetic Acid (TCA) Application Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples Conservative Management of HSIL in Patients With Future Pregnancy Aspiration Clinical Validation of Cervical Cancer Screening Methods Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400) Virtual Reality: Influence on Satisfaction, Pain, and Anxiety in Patients Undergoing Colposcopy Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial DNA Methylation Testing for the Screening of Uterine Cervical Lesion Immunohistochemical Staining of p16 for the Screening of Cervical Cancer CASUS: Validation for Detection of Precursor Lesions CASUS: Improved and Quality Assured Collection of First-void Urine Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Lugol’s Solution in Addition to Acetic Acid During Colposcopy A Phase I Study of E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors Costa Rican Natural History Study of HPV and Cervical Neoplasia Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device Effect of Salpingectomy During Conservative Hysterectomy Feasibility of Delphi Screener for Cervical Cytology Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Gene Therapy Follow up for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) – Types in HIV-positive Men Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY Minimally Invasive Benign Hysterectomy HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 – Brazil) Diagnostic Imaging Aid for Management of Cervical Lesions Cervical Cancer Early Endpoints and Determinants Triage Strategies in Cervical Cancer Prevention Genotypification and Predisposing Factors in Human Papilloma Virus Infection Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Chinese Cancer Prevention Study(CHICAPS) The Development of a “Mother/Child, Screen, Treat and Vaccinate Program” in Manchay and Iquitos, Peru HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings A Trial for Patients With Advanced/Recurrent Cervical Cancer HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer Self-sampling for Non-attenders to Cervical Cancer Screening HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix Human Papillomavirus Epidemiology in Nigeria Impact of HPV Vaccine On The Prevalence Of HPV In Norway Deciphering Mechanisms Underlying Cancer Immunogenicity Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests Spectroscopic Evaluation of Cervical Neoplasia Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3) Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals’ (GSK Bio) HPV-16/18 Vaccine Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women DNA Methylation Biomarkers for Cervical Cancer Screening Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix Can Text Reminders Improve Uptake of Cervical Screening? Comparing Two Techniques of Haemostasis After Cervical Conization A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening FASTER-Tlalpan Study HPV Integration Testing for Human Papillomavirus-Positive Women Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Cervical Cytology – Do SMS Reminders Increase Participation in the Cervical Screening Programme? Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection Effectiveness of Cervical Screening in HPV Vaccinated Women Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples Effect of Fee on Attendance in Cervical Cancer Screening Cervix Cytological Screening – Comparison of Tampon Self-Test and the Routine Smear. Study of the Diagnostic Efficacy of “Real Time” Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix LLETZ Under General Versus Local Anesthesia Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) Trial on Safety and Pharmacokinetics of Intravaginal Curcumin IMproved PRactice Outcomes and Value Excellence in Colposcopy Visual Inspection With Acetic Acid Compared to Lugol’s Iodine in HIV-infected Women Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine Clinical Evaluation of Polarized Light Assisted Colposcopy Indirect Comparison Topotecan Cervical Carcinoma Meta-analysis of Efficacy of Topotecan Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals’ HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study TMTP1-ICG Mapping in Colposcopy-directed Biopsy Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation The HPV Self-test as a Test of Cure in Madagascar REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins Cold Knife Conization With and Without Lateral Hemostatic Sutures DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2 A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake Improving Cervical Cancer Screening Among HIV-Infected Women in India REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Compass – Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia chemQbiosciences:Manual Liquid Based Cytology A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Music Listening to Reduce Pain and Anxiety During LEEP A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia Cervical And Self-Sample In Screening Study Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Factors Associated With Residual Disease In The Central Cone Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Effectiveness of HPV Vaccine in Thai Adult Women Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia Artesunate Vaginal Inserts for the Treatment of CIN2/3 A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) Trial23 – A Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls An Innovative Treatment for Cervical Pre Cancer A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix LLETZ Under Direct Colposcopic Vision The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol Colposcopy and Dynamic Spectral Imaging (DSI) Imiquimod Treatment of High-grade CIN Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Video Colposcopy in Women With Dysplasia Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Imiquimod Treatment of CIN Lesions HPV Integration Testing for Cervical Cancer Screening Hemostatic Procedure After Biopsy of the Cervix HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) Coherence Imaging of the Cervical Epithelium With Scanning a/LCI Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia See and Treat in an Outpatient Setting in Women Above 45 Years With Cervical Dysplasia Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women Smoking Cessation in Women With Gynecological Conditions Recurrence in High-grade Lesions After Conization Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence Management of Cervical Intraepithelial Neoplasia Grade 2 Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) An Innovative Treatment for Cervical Precancer (UH3) Evaluating Materials to Educate Patients About Cervical Dysplasia A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia Performance, Safety, and Efficacy of a New Cryotherapy Device for Cervical Dysplasia [Part II] Music and Colposcopy in Women With Cervical Dysplasia. Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 Focal Ablation of Cervical Precancer Digital Imaging Aid for Assessment of Cervical Dysplasia Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2) Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia Can Alternative Treatment Have an Impact on Cervical Dysplasia? Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

Brief Title

Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study

Official Title

Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study

Brief Summary

      In Singapore, the current cervical cancer screening uptake among women in Singapore has
      remained at low 50% since its introduction in 2004. It has been widely reported that
      under-screened women have the highest risk of cervical cancer. Self-sampling HPV DNA
      screening may be a solution to the low uptake rates of local women, particularly among the
      under-screened population in Singapore. Self-sampling comprises women using a swab to obtain
      samples from their vagina.

      In this study, we are comparing the sensitivity of detecting HPV positive women using HPV DNA
      test with self-sampling using flocked swab with the current physician sampling method. We
      also aim to determine acceptability of self-sampling HPV DNA test using flocked swab in
      cervical cancer screening. Designed as a feasibility study, it will comprise a prospective
      study of 300 women attending clinics in National University Hospital (NUH) and National
      Cancer Institute Singapore (NCIS).
    

Detailed Description

      Cervical cancer is one of the leading causes of death worldwide. The recognition that
      cervical cancer is caused by persistent oncogenic HPV virus has caused a considerable
      paradigm shift in screening and prevention of cervical cancer by the introduction of HPV DNA
      test and the HPV vaccine. HPV DNA test as an alternative to the current and more traditional
      cytology only screening has been shown to have higher sensitivity in detecting high grade
      cervical intraepithelial neoplasia (CIN) to allow for earlier treatment of pre-cancer thus
      preventing development of cervical cancer in future. Singapore as the rest of the world are
      in the transition toward the paradigm shift of using HPV DNA test as part of the cervical
      cancer screening strategy compared to the traditional cytology only screening. However, any
      cancer screening program to make an impact, an uptake of 70% of more is desired and currently
      this strategy resulting to the reduction in cervical cancer incidence are only seen in
      countries adopting an organized cervical cancer screening strategy such as the United
      Kingdom. Currently, HPV DNA testing has widely been shown to be higher sensitivity to pick up
      pre-cancer and allow for earlier treatment of pre-cancer. Uptake for cervical cancer
      screening has remains suboptimal since introduction of the national cervical cancer screening
      using cytology only method in 2004.

      A study published by Jin et.al. in Singapore Medical Journal in 2013 evaluating the progress
      of cervical cancer screening Singapore (CSS) since its introduction showed that CSS did not
      make its aim to get 80% uptake for cervical cancer screening for eligible women using
      cytology only method

      Self-sampling in cervical cancer screening

      Cervical cancer screening with HPV DNA test is more sensitive than cytology only method to
      detect pre-cancer cervical cells. It is now well established that cervical cancer screening
      with HPV DNA test is a much more sensitive method to detect pre-cancer cervical cells
      compared to cytology only method.

      The traditional way of taking a cervical cancer screening involves a physician inserting a
      speculum into the vagina to visualize the cervix and brushing the surface of the cervix using
      a cytology brush or spatula. This will collect exfoliated cervical cells to be sent for
      cytology review to detect any abnormal or pre-cancerous looking cells. Currently HPV DNA test
      is performed using the same method as taking a pap smear. However, various studies have shown
      that for HPV DNA test, self-sampling method is a good alternative to physician sampling
      (Appendix C). Current self-sampling methods in the market are expensive and not cost
      effective especially if targeting under screeners. There are however, various self-sampling
      HPV DNA test device in the market. These devices such as the Delphi Screener are expensive
      and would not be a cost-effective alternative method for women especially in the under
      screeners in Singapore. Studies have shown that those who do not come for regular cervical
      cancer screening are usually associated with a lower socioeconomic background. To encourage
      the under screeners to take up screening, the method should not only be accessible to them
      but also affordable. The Copan Floq swab has already been used in NUH for Chlamydia testing
      and it is highly affordable at 3 SGD per swab. Our study would like to determine that using
      this affordable swab for self-sampling is as sensitive in detecting high risk HPV as a
      physician sampling method.

      There is no local data on the acceptability of self-sampling method using a Floq swab among
      women in Singapore. The acceptability of self-sampling has been reported to be high among
      women especially in the western countries. Women in the Asian population in particular
      Singapore may differ in their acceptability of a self-sampling method compared to a physician
      sampling method. Self-sampling HPV DNA test will require a woman to insert the cotton swab
      into the vagina and currently there is no local data to show wether it is an acceptable
      method for women in Singapore for all ages from 25 to 69 years old. The use of tampons is a
      much more acceptable method during menstruation in the western country which may influence
      the acceptability data of self-sampling in the western countries. However, tampon use is not
      a norm in Asian population including Singapore and may be a factor to influence the
      acceptability of self-sampling among Singaporean women especially in the older age group.

      This study is thus also designed to elucidate this issue. Cervical cancer is a marker of
      health disparities. Looking to the future, data has shown that failure to go for cervical
      cancer screening, which is a highly preventable disease, may also be linked to failure of
      uptake to other screening in a woman. It may also be linked to failure of basic health
      screening not only for the woman but also for her family. Hence to overcome barriers for
      cervical cancer screening especially in giving women a reliable alternative option may in
      future not only help to prevent cervical cancer but also indirectly encourage uptake of other
      screening such as breast cancer and colorectal screening for her and her family. Our study
      will attempt to address two questions. 1) Does the self-sampling HPV DNA test as sensitive as
      the physician sampling HPV DNA test in Singapore? And 2) If Singaporean women have the option
      of self-sampling, are they more likely to regularly participate in future cervical cancer
      screening.

      STUDY DESIGN

      The study is a prospective feasibility study composed of healthy women aged between 30-69
      years who are attending clinics in NUH will be identified through the gynaecologist. Ethical
      approval for this study from the Domain Specific Review Board for O&G is being sought.

      Subjects: Three hundred women who meet the inclusion & exclusion below will be invited to
      participate and complete the consent process. Those that decline will have age, ethnicity,
      education, work status & reason for declining collected.

      Study Visit: Each potential participant will initially see their doctor as clinically
      intended and offered to participate in the study as identified by each physician in the
      clinic. Upon agreeing to participate in the study, each participant will be given a study
      information leaflet and introduced to the research coordination for further explanation of
      the study and to sign the study consent form. Once consent form is signed, the participant
      will be given a study self-sampling kit and instructions on how to perform the self-sampling
      (see Appendix A). The participant performed the self-sampling test in the clinic in a private
      area and hand over the completed kit to the research coordinator who will label and keep the
      sample for process.

      Post assessment: On completion, the participant will be invited to complete a 10 to 15
      minutes questionnaire to assess women's acceptability on self-sampling method. Upon
      completion of the questionnaire, the participant will be awarded a study token of
      appreciation prior to leaving the clinic. The participant clinical management will not be
      affected by the study.

      SAMPLE SIZE AND STATISTICAL ANALYSIS

      Data collected for this study will be in a password protected Microsoft Excel software. Only
      the primary investigator and co-investigators will have access to the database for the
      purpose of data analysis. Sample size was calculated based on the number of women between the
      ages of 30 and 69 in Singapore's population (as of June 2017). Using a 95% confidence level,
      it was determined that a sample size of 120 - 150 women would be ideal. The sample size was
      calculated using G*Power. SPSS will be used to analyze the data collected. Descriptive
      analyses will be done on the survey data to get demographic data, and to determine
      participants' perceptions and ratings of the self-sampling methods. Multivariate analyses
      will be used to determine the sensitivity of the self-sampling method with physician-taken
      swab as the reference standard.

      Data collected will include:

        -  Patient details: Name and NRIC

        -  Patient demographics: Age, Race, area code, parity, social economic status

        -  Reason for HPV DNA test: Primary screening or secondary screening

        -  Screening results:

             -  Physician sampling HPV DNA test

             -  Self-sampling HPV DNA test

        -  Completed questionnaire

      Our specific aims are to:

        1. To determine the sensitivity of self-sampling method compared to physician sampling
           method for HPV DNA test in cervical cancer screening

        2. To determine acceptability of self-sampling HPV DNA test using flocked swab in cervical
           cancer screening

      The study is designed to give a more accurate local view of the sensitivity of floq swab and
      acceptability for self-sampling to Singaporean women. Published studies on self-sampling are
      mainly from the western countries and perception may not be similar for local women.
      Currently available self-sampling in the market are expensive and thus will not be cost
      effective if to be introduced to the current Singapore cervical cancer screening program. As
      Singapore is also moving towards HPV primary screening in the very near future, this study
      will aid in providing the next step to the screening program by introducing a method that can
      help to increase uptake of screening in particular in the underscreen population in
      Singapore.
    


Study Type

Interventional


Primary Outcome

Sensitivity and specificity of self-collected HPV swabs

Secondary Outcome

 Participant acceptability of self-collected HPV swabs

Condition

Cervical Cancer

Intervention

Self-collected HPV vaginal swab

Study Arms / Comparison Groups

 All participants
Description:  Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Diagnostic Test

Estimated Enrollment

300

Start Date

March 2019

Completion Date

December 2019

Primary Completion Date

August 2019

Eligibility Criteria

        Inclusion criteria: All women aged between 30-69 years who are attending clinics in NUH.

        Exclusion criteria:

          1. Women who are pregnant

          2. Previous total hysterectomy

          3. Previous history of cervical cancer

          4. Virgin Intacto

          5. Negative Pap smear less than 3 years ago.
      

Gender

Female

Ages

30 Years - 69 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Ismail Pratt Ida, MBBS, 96564934, [email protected]



Administrative Informations


NCT ID

NCT03813576

Organization ID

2018/00846


Responsible Party

Sponsor

Study Sponsor

National University Hospital, Singapore


Study Sponsor

Ismail Pratt Ida, MBBS, Study Chair, National University Hospital, Singapore


Verification Date

January 2019